PPT Slide

Issues of ‘Other Solid Tumors’ Trial

• Heterogeneous population

• Is there substantial evidence to support efficacy of the 4 mg arm?

• If yes, should Zometa be approved for all solid tumors?

Previous slide

Next slide

Back to first slide

View graphic version